Journal of Neuro-Oncology

, Volume 146, Issue 1, pp 91–95 | Cite as

Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trial

  • Yousra Izzuddeen
  • Subhash GuptaEmail author
  • K. P. Haresh
  • Dayanand Sharma
  • Prashanth Giridhar
  • Gour Kishore Rath
Clinical Study



Diffuse intrinsic pontine glioma (DIPG) is the most common form of brainstem glioma. The present study was performed to assess if hypofractionated radiotherapy completed in < 3 weeks with temozolomide improves survival in DIPG.

Material and methods

The present study is a phase II open label randomized trial. The study included newly diagnosed patients with DIPG. Patients in arm A received conventional fractionated RT of 60 Gy in 30 fractions over 6 weeks while patients in arm B received hypo-fractionated radiotherapy of 39 Gy in 13 fractions over 2.6 weeks along with concurrent Temozolomide (TMZ) 75 mg/m2 from day 1 to day 17 followed by adjuvant TMZ for six cycles. The survival analysis was performed with modified intention to treat analysis.


A total of 35 patients were randomized. 33 patients were evaluable. 93% (n = 14) of patients in the conventional arm completed treatment while only 17% (n = 3) of the children could complete planned course of treatment in the experimental arm. The median overall survival (OS) was 11 months (95% CI − 7.5 to 14.5 months) in the conventional arm and 12 months (95% CI − 10.5 to 13.5 months) in the experimental arm (p = 0.208). 28% (n = 5) patients in the experimental arm developed grade 3 or 4 hematological toxicity.


The above study shows that hypofractionated radiotherapy with concurrent and adjuvant temozolomide does not improve OS and has higher hematological toxicity. Conventional radiotherapy remains the standard of care.


Diffuse intrinsic pontine glioma Hypofractionation Temozolomide 


Compliance with ethical standards

Conflict of interest

No author has any potential conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional ethics committee.

Informed consent

It was obtained from all individual participants included in the study.

Supplementary material

11060_2019_3340_MOESM1_ESM.docx (11 kb)
Supplementary file1 (DOCX 11 kb)


  1. 1.
    Walker DA, Punt JA, Sokal M (1999) Clinical management of brain stem glioma. Arch Dis Child 80(6):558–564CrossRefGoogle Scholar
  2. 2.
    Warren KE (2012) Diffuse intrinsic pontine glioma: poised for progress. Front Oncol 2:205CrossRefGoogle Scholar
  3. 3.
    Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E et al (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol 13(4):410–416CrossRefGoogle Scholar
  4. 4.
    Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME et al (1999) There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 43(5):959–964CrossRefGoogle Scholar
  5. 5.
    Chassot A, Canale S, Varlet P, Puget S, Roujeau T, Negretti L et al (2012) Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol 106(2):399–407CrossRefGoogle Scholar
  6. 6.
    Zaghloul MS, Eldebawy E, Ahmed S, Mousa AG, Amin A, Refaat A et al (2014) Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol 111(1):35–40CrossRefGoogle Scholar
  7. 7.
    Jalali R, Raut N, Arora B, Gupta T, Dutta D, Munshi A et al (2010) Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 77(1):113–118CrossRefGoogle Scholar
  8. 8.
    Frappaz D, Schell M, Thiesse P, Marec-Bérard P, Mottolese C, Perol D et al (2008) Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro-oncology 10(4):599–607CrossRefGoogle Scholar
  9. 9.
    Korones DN, Fisher PG, Kretschmar C, Zhou T, Chen Z, Kepner J et al (2008) Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. Pediatr Blood Cancer 50(2):227–230CrossRefGoogle Scholar
  10. 10.
    Bernier-Chastagner V, Grill J, Doz F, Bracard S, Gentet JC, Marie-Cardine A et al (2005) Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study. Cancer 104(12):2792–2797CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Radiation OncologyAll India Institute of Medical SciencesNew DelhiIndia
  2. 2.Department of Radiation Oncology, National Cancer InstituteAll India Institute of Medical SciencesBadsaIndia

Personalised recommendations